

Annual General Meeting Management Update

2025-06-30



Forward Looking Statement






This presentation may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors. The forward-looking statements contained herein are expressly qualified by this cautionary statement and are made as of the date hereof. The Companies disclaim any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact

Donald McCaffrey
1 403 690 8887
don@resverlogix.com




Introduction to Resverlogix

	Resverlogix	Focus Area: Cardiovascular Disease 
Founded	2001	<p> Apabetalone works in concert with Standard of care (SoC) cardiovascular and diabetic drugs (GLP-1 RA, SGLT2i, DPP4i, statins, ACEi, ARBs, insulin, & more)</p> <p> Cardioprotective benefits, including reducing heart failure, observed beyond SoC</p> <p> Supplementary bioavailability study completed in renally-impaired/dialysis patients</p> <p> Strong potential for expanding indications</p> <p>Apabetalone's clinical development programs are well aligned with pharma's therapeutic focus areas</p>
Headquarters	Calgary, Canada	
Ownership	Publicly-traded (TSX:RVX)	
Focus Area	Cardiometabolic	
Key Leadership	Donald McCaffrey, President & CEO	
	Brad Cann, CFO	
	Dr. Ewelina Kulikowski, CSO	
Capital Raised	>\$500M	
Lead Compound	Apabetalone (Phase 3)	



Financing Concept – Zenith + Resverlogix



- ~50% of the M&A proceeds will be **reinvested** in apabetalone's clinical development to fuel **long-term value creation** for both Resverlogix and ZCC
- Right of first refusal promotes **long-term partnership** with acquiring pharma

ZEN-3694: Multiple Paths to Approval

The unique potential of BET inhibition, coupled with our combinatorial approach, has opened several promising development avenues

ZEN-3694 Clinical Development

- ➔ Efficacy in multiple tumor types
- ➔ Prevents and reverses drug resistance
- ➔ Tolerated in combination with approved therapies

Phase 2 – NUT Carcinoma

Short potential timeline to approval

\$400MM

Peak est.
annual sales

Phase 2b – Metastatic Castration Resistant Prostate Cancer (mCRPC)

Large potential market

\$1.0B

Peak est.
annual sales

Preclinical – Myelofibrosis

Gap in pipeline, due to recent failures

\$2.4B

Est. market
size (2021)






Phase 1/2 – Other Solid Tumors

Ovarian, lung, breast, colorectal, and more

11

Active CRADA
funded trials

Resverlogix's Lead Candidate – Apabetalone

-  Orally-available, selective BET inhibitor
-  Well-tolerated – clear safety record with chronic administration
-  Demonstrated cardio-protective benefits – BETonMACE (Phase 3)
-  Synergistic benefits in combination with SGLT2i
-  Enhanced efficacy in renally-impaired subpopulation

Priority Indications

Phase 3 Heart Failure w/ Diabetes

Phase 2 Post COVID Conditions



Robust Intellectual
Property Protection
(to 2041)



FDA Breakthrough
Therapy Designation



40+ peer-reviewed
publications
(incl. **Cell**, **Nature**)



4200+ patient-years of
FDA-reviewed safety
data



Detailed **proteomic** &
transcriptomic
analyses



Apabetalone Revenue Forecast – \$16B Peak Sales

Commercial Inputs (ACS)

Total Incidence (ACS) 167 – 356 per 100K pop.

Diabetes Prev. 22.5% – 41.2%

Low HDL-C 41.1% - 53.0%

Patients Treated 70.0% – 90.3%

SGLT2i Treatment Up to 32.0%


Launch Year H1 2028 (US)
H2 2028 (Ex-US)

Time to Peak 5 years

Market Share 70%

Annual Price (\$ USD) \$6,700 (US)

Global Lifetime Revenue Forecast in ACS, Diabetes and PCC (USD \$, M)



Commercial Inputs (PCC)

Total Pop. UN data

COVID-19 Cases WHO data

PCC Prev. 20.6% – 57.8% of COVID pop.

Diabetes Prev. 4.1% – 23.1%

SGLT2i Treatment Up to 32.0%


Launch year H1 2028 (US)
H2 2028 (Ex-US)

Time to peak 2 years


Market share 70%

3Month Course (\$ USD) \$1,700 (US)

COVID-19: Apabetalone and Disease Progression




COVID-19: Apabetalone and Disease Progression



Post COVID-19 Cardiovascular Outcomes:

Increased Burden of Multiple Cardiovascular Events



People who contract COVID-19 have a **50%-70% greater risk** of severe cardiac events in the first year after their infection than people who never contracted COVID-19

Adapted from: Xie et al. 2022 (Nature Medicine)

MACE is a composite endpoint of myocardial infarction, stroke, and cardiovascular death



Post Covid Condition (PCC) Trial Update

- Study of apabetalone in PCC conducted in Middle East
- 8 total sites participating
 - Across 4 countries

Key Milestones *(estimated)*


October
2025

Full Enrollment

February
2026

Last Patient, Last Visit

PCC Trial Clinical Sites



Contact

Donald McCaffrey | President & CEO

1 403 690 8887

don@resverlogix.com

